Quick answer
What is ipamorelin, in one profile? Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C38H49N9O5, about 711.9 g/mol), that acts as an agonist at the growth hormone secretagogue (ghrelin) receptor. In rat pituitary cells it released GH with potency and efficacy similar to GHRP-6, and in swine it did so without the ACTH and cortisol rise seen with GHRP-6 and GHRP-2. This page is a one-stop research profile: an identity card, an evidence map by model system, a short glossary and pointers to the detailed guides. The V8 product is a 10 mg lyophilized powder with purity stated as ≥98% by HPLC. Laboratory research use only.
A research profile answers the questions a new reader asks first: what is this molecule, what has been done with it, in which systems, and what is still unknown? It is deliberately compact and links outward for depth. For a long-form coverage see the ipamorelin research overview and what is ipamorelin; this profile instead organizes the facts into tables a bench scientist can scan. Product facts come from the ipamorelin 10 mg product page.
Identity card
| Attribute | Detail |
|---|---|
| Name | Ipamorelin |
| Class | Synthetic growth hormone secretagogue (GHRP-type pentapeptide) |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular formula | C38H49N9O5 |
| Approximate molecular weight | 711.9 g/mol |
| Notable features | N-terminal Aib; two D-aromatic residues; C-terminal amide; no Cys, Met, Trp, Asn or Asp |
| Receptor | GH secretagogue (ghrelin) receptor, a G-protein-coupled receptor |
| Form supplied | Lyophilized powder, sealed clear glass research vial, 10 mg |
| Purity stated | ≥98% by HPLC (product page) |
| Storage stated | 2–8 °C; −20 °C for long-term; protect from heat, moisture and light |
| Certificate | In the COA library where published |
The residue-level reasoning for the structure is in ipamorelin structure and synthesis. Briefly, the Aib and D-residues limit enzymatic access, and the lack of the common oxidation- and deamidation-prone residues makes the sequence chemically conservative.
Evidence map by model system
| System | What was reported | Source |
|---|---|---|
| Rat primary pituitary cells | GH release with potency and efficacy similar to GHRP-6 (EC50 1.3 vs 2.2 nmol/L) | Raun 1998 |
| Rats (in vivo) | GH release; ED50 and Emax similar to GHRP-6 | Raun 1998 |
| Swine | GH release without significant ACTH or cortisol rise; no effect on FSH, LH, PRL or TSH | Raun 1998 |
| Adult female rats, 15 days | Dose-dependent rise in longitudinal bone growth rate; total IGF-I and IGFBPs unchanged | Johansen 1999 |
| Aged female rats, 3 months | With a glucocorticoid, higher muscle tension and periosteal bone formation than glucocorticoid alone | Andersen 2001 |
| Healthy volunteers (PK/PD model) | Terminal half-life about 2 h; GH episode peaking at about 0.67 h | Gobburu 1999 |
The first four rows are what makes ipamorelin a useful tool compound: a defined receptor target, a clean selectivity profile and consistent animal-model behavior. The last row is published pharmacokinetic and pharmacodynamic modeling; details and formulas are in ipamorelin pharmacokinetics.
How it compares with neighboring secretagogues
| Peptide | Length | Receptor | Notable point in the cited work |
|---|---|---|---|
| Ipamorelin | 5 | GHRP-like receptor | No significant ACTH or cortisol rise in swine |
| GHRP-6 | 6 | GHRP-like receptor | Reference for potency; raised ACTH and cortisol in swine; GH release not blocked by a GRF antagonist |
| GHRP-2 | 6 | GHRP-like receptor | Higher potency, lower efficacy than ipamorelin in rats; raised ACTH and cortisol in swine |
| GHRH analogs (e.g. CJC-1295 no DAC) | 29 | GHRH receptor (cAMP) | Distinct receptor; synergy with GHRP-6 shown in rat pituitary cells |
See ipamorelin vs GHRP-6, ipamorelin vs GHRP-2 and CJC-1295 vs ipamorelin for full comparisons.
Glossary
- Aib: aminoisobutyric acid, a non-proteinogenic residue with two methyl groups on the alpha carbon.
- D-2-Nal: D-2-naphthylalanine, a D-configured aromatic residue.
- GHRP: growth-hormone-releasing peptide, a family of synthetic secretagogues.
- GHRH: growth-hormone-releasing hormone, the hypothalamic peptide acting at a separate receptor.
- Ghrelin: the natural ligand of the secretagogue receptor, purified from stomach.
- EC50 / ED50: concentration or amount giving half the maximal effect in vitro or in vivo.
- Emax: maximal response.
- Lyophilized: freeze-dried to a stable solid.
Why it is used as a tool compound
Three properties explain why laboratories choose a peptide like this. The first is receptor definition: the target is a cloned G-protein-coupled receptor with a known natural ligand, so a result can be tied to a specific protein (Howard 1996; Kojima 1999). The second is the selectivity profile described in the original paper, which lets a researcher attribute a GH response without the confounding pituitary–adrenal read-outs seen with older secretagogues in the swine experiment (Raun 1998). The third is chemical conservatism: the sequence has few reactive residues, so a well-handled stock behaves predictably across a series of experiments.
These are reasons to select the compound for a design, not claims about outcomes. A good experiment still includes a reference secretagogue, a vehicle control and the receptor-level controls described in the mechanism article, and it reports the lot and handling used.
Quality and documentation checklist
| Check | Where to look |
|---|---|
| Identity (sequence, formula, mass) | Product page and, where published, the certificate |
| Purity by HPLC | Product page states ≥98%; certificate where published |
| Net peptide content | Not implied by purity; account for it in molar calculations |
| Storage history | Notebook log of temperatures and dates |
| Reconstitution record | Diluent, volume, concentration formula, date |
| Appearance | Cake and solution clarity at each use |
The explainer how to read a COA walks through the certificate fields, and understanding HPLC purity explains the percentage. Neither makes a claim about any particular lot.
Reading list by question
| If your question is… | Start with |
|---|---|
| How was it discovered? | The development-history article and the 1981, 1984 and 1998 primary papers |
| What does it bind and how does it signal? | The mechanism article and the 1996 receptor-cloning paper |
| How do I prepare a stock? | The reconstitution guide and the calculator |
| How long will a stock last? | The storage and stability article |
| What is known about exposure and half-life? | The pharmacokinetics article and the 1999 modeling paper |
| How does it compare with GHRP-6 or GHRP-2? | The two comparison articles |
What a profile cannot tell you
A profile compresses many papers into a few rows, and compression removes context. It cannot tell you how a result was affected by the assay format, the passage number of the cells, the species strain, the time of day of sampling or the number of animals. It cannot tell you whether a finding has been independently reproduced, because most of the findings here rest on one report per system. It also cannot replace reading the methods of the specific paper before borrowing a design from it. Use each row as a pointer to a paper, and read the paper.
A related caution concerns older literature. Several of the primary sources date from the 1980s and 1990s, when assays, reference standards and reporting norms were different from today’s. Potency values can shift with assay generation, and abstracts may omit details such as the number of independent experiments. When replicating a result, expect to re-establish the dose-response curve in your own hands rather than to match a published number exactly, and report the difference as a finding if it occurs.
Open questions
The sources used here leave several questions open, and a good profile names them. Whether ipamorelin shows biased signaling at its receptor, how it behaves in human cell systems, how its desensitization compares with GHRP-6, whether selectivity holds in other species, and how long the intact peptide persists in common culture media are not settled by these papers. The mechanism guide, ipamorelin mechanism and controls, frames several of these as experiments, and the history in ipamorelin development history puts them in context.
Where to go next
For preparation, see the reconstitution guide and storage and stability; for verification, ipamorelin purity testing and the COA library; for arithmetic, the reconstitution calculator; for the catalog, the shop page. For sourcing criteria in general, see the sourcing checklist. All material is for laboratory research use only; not for human or animal consumption.
Using this profile responsibly in a methods section
A profile is a starting point, not a citation. When writing methods, cite the primary paper for each statement, name the species and system, and state the lot and handling of the material used. Avoid summarizing the evidence as general properties of the molecule when it was measured in one assay. For example, “ipamorelin released GH from rat primary pituitary cells with an EC50 of 1.3 nmol/L” is accurate and checkable, while “ipamorelin is potent” is not. The same applies to the selectivity statement, which was tested against a defined hormone panel in swine, and to the bone-growth findings, which were obtained with specific schedules in rats. Reporting at that level of detail also lets a reader decide whether a result is relevant to a different system.
Finally, record peptide quality alongside biology. Purity by HPLC is a chromatographic measure, identity needs a mass check, and net peptide content determines the true molar concentration. Writing the concentration as C = m / (MW × V) with the assumptions stated makes the number reproducible.
Frequently asked questions
What is ipamorelin?
A synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that acts at the growth hormone secretagogue (ghrelin) receptor and was described in 1998 as the first selective GH secretagogue.
What are its formula and molecular weight?
C38H49N9O5 and about 711.9 g/mol.
Which receptor does it act on?
The GH secretagogue receptor, a G-protein-coupled receptor that also binds ghrelin, rather than the GHRH receptor.
What made it stand out in the original paper?
In swine it released GH without significantly raising ACTH or cortisol, unlike GHRP-6 and GHRP-2.
How potent was it in vitro?
In rat pituitary cells it released GH with an EC50 of 1.3 nmol/L and an Emax of 85%, compared with 2.2 nmol/L and 100% for GHRP-6.
What animal studies exist beyond the original paper?
Rat studies on longitudinal bone growth over 15 days and on glucocorticoid-related muscle and bone endpoints over three months.
Is there published pharmacokinetic modeling?
Yes, a volunteer PK/PD modeling study reported a terminal half-life of about 2 hours; see the pharmacokinetics article for the formulas and caveats.
What does the V8 product page state?
A 10 mg lyophilized powder in a sealed clear glass research vial, purity ≥98% by HPLC, stored at 2–8 °C with −20 °C for long-term holding.
Where can I find a certificate?
In the COA library, where one has been published for the lot.
Is this profile guidance for use?
No. It summarizes published cell and animal findings for laboratory research reference.
Related reading: Ipamorelin Stability: Storage and Degradation Pathways, Ipamorelin Structure and Synthesis: Aib, D-2-Nal, Amide, Ipamorelin and CJC-1295: Receptor Synergy Research.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. doi:10.1054/ghir.1999.9998
- Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. doi:10.1054/ghir.2001.0239
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/A:1018955126402
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
